{"gene":"STAT3","run_date":"2026-06-10T07:46:42","timeline":{"discoveries":[{"year":1994,"finding":"APRF (STAT3) associates physically with both the IL-6 signal transducer gp130 and the Jak1 protein kinase upon stimulation by IL-6-family cytokines, and undergoes tyrosine phosphorylation in this complex, establishing that Jak family kinases participate in IL-6 signaling via STAT3.","method":"Co-immunoprecipitation, tyrosine phosphorylation assays, DNA-binding assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP of endogenous proteins, replicated across multiple cytokines and cell types, foundational paper with multiple orthogonal methods","pmids":["8272872"],"is_preprint":false},{"year":1995,"finding":"Growth hormone (GH) activates STAT3 by promoting tyrosine phosphorylation of STAT3, enabling it to bind DNA elements (SIE in c-fos promoter and APRE in alpha2-macroglobulin promoter), demonstrating GH signals through multiple STAT proteins including STAT3.","method":"Immunoprecipitation with anti-STAT3 antibodies, tyrosine phosphorylation assay, gel shift/DNA-binding assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tyrosine phosphorylation and DNA-binding assays in single lab with two orthogonal methods","pmids":["7876144"],"is_preprint":false},{"year":1999,"finding":"Substitution of two cysteine residues within the C-terminal loop of the STAT3 SH2 domain (Stat3-C) produces a molecule that dimerizes spontaneously, binds DNA constitutively, activates transcription, and causes cellular transformation (soft agar colony formation, nude mouse tumor formation), demonstrating that constitutively active STAT3 alone is sufficient to mediate oncogenic transformation.","method":"Site-directed mutagenesis, dimerization assay, DNA-binding assay, transcriptional reporter assay, soft agar colony formation, nude mouse xenograft","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — active-site mutagenesis with multiple functional readouts (in vitro dimerization, DNA binding, transcription, transformation, tumor formation) in a single rigorous study","pmids":["10458605"],"is_preprint":false},{"year":1997,"finding":"HGF/SF activates STAT3 in human hepatocytes and hepatoma cells (HepG2) via the JAK/STAT pathway; unlike IL-6-induced rapid and transient STAT3 activation, HGF/SF-induced STAT3 activation is delayed (5–7 h) and sustained (up to 28 h).","method":"Transcription factor activation assay, kinetic analysis in primary hepatocytes and HepG2 cells","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct STAT3 activation assays in two cell types with defined kinetics, single lab","pmids":["9094433"],"is_preprint":false},{"year":2002,"finding":"Zebrafish Stat3 is activated on the dorsal side by the maternal Wnt/beta-catenin pathway and is required cell-autonomously for anterior migration of dorsal mesendodermal cells and non-cell-autonomously for convergence of paraxial cells during gastrulation; loss of Stat3 causes abnormal gastrulation movements without defects in early cell fate specification.","method":"Dominant-negative Stat3 expression, cell tracing, transplantation experiments, time-course analysis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Wnt/beta-catenin upstream of Stat3), cell-autonomous vs non-autonomous dissection via transplantation, multiple orthogonal methods","pmids":["11879641"],"is_preprint":false},{"year":2003,"finding":"STAT3 nuclear export is regulated by multiple nuclear export signal (NES) elements: NES Stat3(306-318) mediates post-stimulation export, while Stat3(404-414) and Stat3(524-535) regulate basal nuclear export. LMB (leptomycin B) blocks post-stimulation export and also causes nuclear accumulation of unphosphorylated Stat3 in resting cells, revealing a tyrosine phosphorylation-independent basal nuclear export pathway.","method":"Leptomycin B treatment, NES mutagenesis, subcellular fractionation/localization assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NES mutagenesis combined with pharmacological blockade and subcellular localization, single lab but multiple orthogonal approaches","pmids":["12588893"],"is_preprint":false},{"year":2003,"finding":"Tip60 (a histone acetyltransferase) physically associates with endogenous STAT3 and represses STAT3-driven transcription by recruiting HDAC7 through its N-terminal zinc finger region; overexpression of Tip60 abrogates IL-9-induced STAT3-dependent c-myc expression.","method":"Co-immunoprecipitation of endogenous proteins, reporter gene assay, siRNA/overexpression, endogenous target gene (c-myc) measurement","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous Co-IP plus functional transcription assays, single lab","pmids":["12551922"],"is_preprint":false},{"year":2004,"finding":"STRA13 binds predominantly to phosphorylated (active) STAT3α and STAT3β isoforms via its HLH and C-terminal regions, activates transcription from STAT-dependent elements, and modulates STAT3-regulated pro-apoptotic Fas gene promoter activity; co-expression of STRA13 with STAT3β alleviates STRA13's pro-apoptotic effect.","method":"Yeast two-hybrid screening, GST pulldown/Co-IP with phosphorylated STAT3, reporter gene assay, apoptosis assay","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid identification confirmed by binding assay with phosphorylated STAT3, functional transcriptional and apoptosis readouts, single lab","pmids":["15223310"],"is_preprint":false},{"year":2004,"finding":"In mast cells and melanocytes stimulated via gp130 or c-Kit receptors, cytokine-induced phosphorylation of MITF at S409 causes dissociation of PIAS3 from MITF and its re-association with STAT3, thereby modulating STAT3-dependent gene expression; cells from MITF(di/di) mice (lacking the PIAS3-binding Zip domain of MITF) show downregulation of genes regulated by either MITF or STAT3.","method":"Co-immunoprecipitation, phosphorylation assays, mRNA expression analysis in MITF mutant cells, cell stimulation via gp130/c-Kit","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing dynamic PIAS3 redistribution between MITF and STAT3 with functional gene expression readout in genetic model, single lab","pmids":["15572665"],"is_preprint":false},{"year":2005,"finding":"Oncogenic Stat3 binds to the p53 gene promoter in vitro and in vivo (ChIP), and site-specific mutation of a Stat3 DNA-binding site in the p53 promoter partially abrogates Stat3-induced inhibition; blocking Stat3 in cancer cells upregulates p53 expression leading to p53-mediated apoptosis, placing Stat3 as a transcriptional repressor of p53.","method":"Chromatin immunoprecipitation (ChIP), promoter reporter assay with site-directed mutagenesis, Stat3 inhibition/knockdown with p53 expression and apoptosis readout","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP showing in vivo binding plus promoter mutagenesis abrogating repression plus functional knockdown rescue, multiple orthogonal methods in single study","pmids":["16107692"],"is_preprint":false},{"year":2005,"finding":"Cytoplasmic (non-tyrosine-phosphorylated) STAT3 mediates cell migration by associating with stathmin, potentiating microtubule polymerization; this disrupts the stathmin-microtubule interaction and promotes cell movement.","method":"Co-immunoprecipitation/pulldown of STAT3 with stathmin, microtubule polymerization assay, cell migration assay","journal":"Science's STKE","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying STAT3-stathmin interaction with functional microtubule polymerization and migration readout, single lab","pmids":["16835434"],"is_preprint":false},{"year":2005,"finding":"STAT3 is constitutively associated (~5%) with the early endosome fraction; after IL-6 treatment, up to two-thirds of cytoplasmic tyrosine-phosphorylated STAT3 associates with early endosomes. STAT3 transcriptional activation is inhibited by dominant-negative dynamin K44A, epsin 2a, amphiphysin A1, and clathrin light chain, but enhanced by active dynamin MxA, demonstrating that endocytic trafficking is required for productive IL-6/STAT3 signaling.","method":"Cell fractionation, electron microscopy, immunofluorescence, detergent dissection, transient transfection with dominant-negative/active endocytic regulators and STAT3-reporter luciferase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (EM, immunofluorescence, fractionation, functional reporter with dominant mutants) demonstrating endosomal STAT3 localization with functional consequence","pmids":["16407171"],"is_preprint":false},{"year":2005,"finding":"ZIP kinase (ZIPK) physically interacts specifically with STAT3 (but not STAT1, STAT4, STAT5a, STAT5b, or STAT6), phosphorylates STAT3 on Ser727 in the nucleus, and enhances STAT3 transcriptional activity; siRNA knockdown of ZIPK decreases LIF- and IL-6-induced STAT3-dependent transcription.","method":"Co-immunoprecipitation, in vitro kinase assay with phospho-Ser727 detection, siRNA knockdown, transcriptional reporter assay","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase assay identifying STAT3-Ser727 as ZIPK substrate plus Co-IP and siRNA functional validation, single lab","pmids":["16219639"],"is_preprint":false},{"year":2007,"finding":"KAP1/TIF1beta (a universal corepressor) physically associates with endogenous STAT3 in vivo; siRNA-mediated knockdown of KAP1 enhances IL-6-induced STAT3-dependent transcription and causes marked accumulation of Ser727-phosphorylated STAT3 in the nucleus, indicating KAP1 negatively regulates the IL-6/STAT3 signaling pathway.","method":"Yeast two-hybrid screening, Co-IP of endogenous proteins, siRNA knockdown, transcriptional reporter assay, nuclear pSer727-STAT3 immunostaining","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous Co-IP confirmed by functional siRNA transcription assay, single lab","pmids":["18037959"],"is_preprint":false},{"year":2008,"finding":"A JAK2/STAT2/STAT3 signaling axis (distinct from the JAK1/STAT1/STAT3 proliferation pathway) is required for early myogenic differentiation; inhibition by small molecule JAK2 inhibitor or siRNA against JAK2, STAT2, or STAT3 blocks myogenic differentiation. The pro-differentiation effect is partially mediated through MyoD, MEF2, IGF2, and HGF gene regulation.","method":"siRNA knockdown of JAK2/STAT2/STAT3, small molecule JAK2 inhibitor, differentiation assays, qPCR for MyoD/MEF2/IGF2/HGF","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown and pharmacological inhibition with differentiation phenotype and target gene readouts, single lab","pmids":["18835816"],"is_preprint":false},{"year":2010,"finding":"STAT3 acts as a transcription factor for the S1PR1 gene; reciprocally, S1PR1 activates STAT3 (in part by upregulating JAK2 kinase activity) and upregulates IL-6 expression, forming a positive feedback loop that sustains persistent STAT3 activation in cancer cells. S1P-S1PR1-induced STAT3 activation is persistent, in contrast to transient IL-6-induced STAT3 activation.","method":"Chromatin immunoprecipitation, S1PR1 silencing (siRNA/shRNA) in tumor cells and immune cells, xenograft tumor growth/metastasis assay, JAK2 activity assay","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP identifying STAT3 as S1PR1 transcription factor, functional silencing in multiple contexts (tumor cells, immune cells, in vivo), mechanistic validation of JAK2 upregulation, multiple orthogonal methods","pmids":["21102457"],"is_preprint":false},{"year":2012,"finding":"STAT3 directly interacts with Hsp90β with high affinity (surface plasmon resonance of recombinant proteins); this interaction requires a functional DNA-binding domain (RR414/417); the interaction is not preferentially altered by a phosphomimetic mutation at tyrosine 705.","method":"Surface plasmon resonance spectroscopy with recombinant proteins, site-directed mutagenesis of STAT3 (RR414/417A), DNA-binding oligonucleotide pulldown, confocal colocalization in MCF7 cells","journal":"IUBMB life","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct in vitro SPR with recombinant proteins plus mutagenesis validating DNA-binding domain requirement, single lab","pmids":["22271514"],"is_preprint":false},{"year":2014,"finding":"STAT3 is simultaneously phosphorylated at Thr714 and Ser727 by GSK-3α/β to form a noncanonical phosphoform that drives STAT3-dependent gene induction independently of Tyr705 phosphorylation in response to combined EGFR and PAR-1 activation; both residues are required and depletion of GSK-3α/β is sufficient to disrupt this signal integration. Doubly phosphorylated STAT3 (but not pTyr705-STAT3) is elevated in clear-cell renal-cell carcinoma.","method":"Quantitative LC-MS/MS mass spectrometry, site-directed mutagenesis of Thr714/Ser727, GSK-3α/β depletion (siRNA), STAT3-dependent reporter assay, clinical tissue comparison","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — MS discovery of novel phosphoform confirmed by mutagenesis, kinase depletion with gene expression readout, and clinical validation; multiple orthogonal methods in single study","pmids":["24615012"],"is_preprint":false},{"year":2015,"finding":"Activated STAT3 directly interacts with Smad3 in vivo and in vitro; this interaction attenuates Smad3-Smad4 complex formation and suppresses Smad3 DNA-binding ability, antagonizing TGF-β signaling. The N-terminal region of the STAT3 DNA-binding domain is responsible for the STAT3-Smad3 interaction and is indispensable for STAT3-mediated TGF-β inhibition.","method":"Co-immunoprecipitation in vivo and in vitro pulldown, STAT3/Smad3 domain mapping, Smad3-Smad4 complex disruption assay, DNA-binding assay, STAT3 knockdown with TGF-β response readouts (cell cycle arrest, apoptosis, EMT)","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro and in vivo interaction confirmed, domain mapping, mechanistic disruption of Smad3-Smad4 complex, functional knockdown with multiple phenotypic readouts, multiple orthogonal methods","pmids":["26616859"],"is_preprint":false},{"year":2018,"finding":"ZNF341, a zinc finger transcription factor, binds to and activates the STAT3 promoter; loss-of-function mutations in ZNF341 reduce STAT3 expression and result in an AD-HIES-like immunodeficiency phenotype with decreased Th17 cells, establishing ZNF341 as a direct transcriptional regulator of STAT3 expression.","method":"Promoter binding assay (ZNF341 binding to STAT3 promoter), luciferase reporter assay, nuclear translocation analysis of mutant ZNF341, patient-derived cell characterization, STAT3 mRNA/protein quantification","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter binding by ZNF341 with transcriptional activation assay, mutagenesis showing loss of function, replicated in four consanguineous families with consistent phenotype","pmids":["29907690"],"is_preprint":false},{"year":2023,"finding":"IL-6-independent STAT3 Y705 phosphorylation at early stages of influenza A virus (IAV) infection is dependent on the RIG-I/MAVS/Syk signaling axis; STAT3 Y705 phosphorylation restrains IAV pathogenesis by repressing excessive production of type I and III interferons. STAT3Y705F knockin mice show impaired antiviral gene expression, severe lung injury, and poor survival; knockout of IFNAR1 or IFNLR1 in STAT3Y705F mice rescues lung injury and reduces viral load.","method":"STAT3-Y705F knockin mice, IAV infection model, IFN expression measurement, genetic epistasis (IFNAR1/IFNLR1 knockout in knockin background), viral load quantification","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockin mouse model with Y705F mutation, genetic epistasis rescue by IFN receptor knockout, multiple in vivo phenotypic readouts establishing mechanistic pathway","pmids":["37440406"],"is_preprint":false},{"year":2022,"finding":"VDR and phosphorylated STAT3 (phosphorylated by JAK2 specifically in response to vitamin D stimulation) interact with each other and with the DNA demethylase TET2 to form a complex that drives DNA demethylation and transcriptional activation at VDR binding sites, establishing tolerogenesis in dendritic cells; pharmacological JAK2 inhibition reverts vitamin D-induced tolerogenic properties.","method":"Co-immunoprecipitation of VDR-pSTAT3-TET2 complex, JAK2 inhibitor treatment, DNA methylation analysis, DC tolerogenesis functional assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying trimeric complex, pharmacological epistasis confirming JAK2-STAT3 requirement for tolerogenesis, single lab","pmids":["35045292"],"is_preprint":false},{"year":2000,"finding":"Conditional knockout of STAT3 specifically in mammary gland epithelium (using lox/Cre system) causes decreased epithelial apoptosis and dramatic delay of mammary gland involution upon forced weaning, demonstrating that STAT3 is required for initiation of physiological apoptosis during mammary involution in vivo.","method":"Conditional gene knockout (lox/Cre), mammary gland involution assay, apoptosis quantification, STAT1/p53/p21 expression analysis","journal":"Advances in experimental medicine and biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic knockout with specific in vivo phenotypic readout (impaired apoptosis/involution), complementary pathway analysis","pmids":["10959419"],"is_preprint":false}],"current_model":"STAT3 is a latent cytoplasmic transcription factor that is activated by tyrosine phosphorylation (primarily at Y705) by JAK-family kinases downstream of cytokine receptors (e.g., gp130/JAK1 for IL-6-family cytokines) and growth factor receptors; upon phosphorylation it dimerizes via SH2-phosphotyrosine interactions, translocates to the nucleus via a CRM1-dependent export pathway regulated by multiple NES elements, and activates or represses target genes (including S1PR1, p53, and IFN-response genes); its activity is further modulated by Ser727 phosphorylation (by ZIPK and GSK-3α/β), non-canonical Thr714/Ser727 dual phosphorylation by GSK-3, interaction with co-repressors (Tip60/HDAC7, KAP1), direct binding to Smad3 to antagonize TGF-β signaling, cytoplasmic sequestration of stathmin to promote microtubule polymerization and cell migration, mitochondrial localization where it regulates electron transport chain activity, and transcriptional control of STAT3 expression itself by ZNF341; constitutively activating mutations in the SH2 domain (Stat3-C) are sufficient for oncogenic transformation."},"narrative":{"mechanistic_narrative":"STAT3 is a latent cytoplasmic transcription factor that transduces signals from cytokine and growth factor receptors to the nucleus, where it activates and represses target genes governing proliferation, apoptosis, differentiation, and migration [PMID:8272872, PMID:10458605]. It is recruited to the IL-6 signal transducer gp130 together with the Jak1 kinase and undergoes tyrosine phosphorylation within this complex [PMID:8272872], and is similarly activated by growth hormone and HGF/SF through the JAK/STAT pathway, with HGF/SF producing delayed and sustained activation in contrast to the transient IL-6 response [PMID:7876144, PMID:9094433]. Productive IL-6/STAT3 signaling further requires endocytic trafficking, as tyrosine-phosphorylated STAT3 associates with early endosomes and transcriptional output depends on intact clathrin/dynamin-mediated endocytosis [PMID:16407171]. Nuclear residence is controlled by multiple CRM1-dependent nuclear export signals, including a post-stimulation NES and basal NES elements that export even unphosphorylated STAT3 [PMID:12588893]. Beyond canonical Tyr705 phosphorylation, STAT3 activity is tuned by Ser727 phosphorylation by ZIP kinase, which enhances transcription [PMID:16219639], and by a noncanonical dual Thr714/Ser727 phosphorylation by GSK-3α/β that drives gene induction independently of Tyr705 upon EGFR/PAR-1 co-activation [PMID:24615012]. As a sequence-specific factor STAT3 represses the p53 promoter to restrain apoptosis [PMID:16107692] and transcriptionally activates S1PR1 in a feed-forward loop with IL-6/JAK2 that sustains persistent activation in tumors [PMID:21102457]. Its output is constrained by corepressors that physically associate with STAT3, including Tip60/HDAC7 and KAP1/TIF1β [PMID:12551922, PMID:18037959]. STAT3 also acts through non-transcriptional and protein-protein routes: cytoplasmic unphosphorylated STAT3 binds stathmin to promote microtubule polymerization and cell migration [PMID:16835434], and activated STAT3 binds Smad3 to disrupt Smad3-Smad4 complex formation and antagonize TGF-β signaling [PMID:26616859]. STAT3 expression itself is directly driven by the zinc-finger transcription factor ZNF341, whose loss-of-function causes an autosomal-dominant hyper-IgE syndrome-like immunodeficiency [PMID:29907690]. In vivo, STAT3 is required for physiological epithelial apoptosis during mammary gland involution [PMID:10959419] and for restraining excessive type I/III interferon production during influenza A infection [PMID:37440406].","teleology":[{"year":1994,"claim":"Established how STAT3 is activated, by showing it physically engages the gp130 receptor and Jak1 kinase upon IL-6-family cytokine stimulation and is tyrosine-phosphorylated in that complex.","evidence":"Reciprocal Co-IP of endogenous proteins, tyrosine phosphorylation and DNA-binding assays across cytokines/cell types","pmids":["8272872"],"confidence":"High","gaps":["Did not resolve the phosphorylation site stoichiometry or dimer geometry","Did not address receptors beyond the IL-6 family"]},{"year":1995,"claim":"Extended the activation repertoire beyond cytokines by showing growth hormone tyrosine-phosphorylates STAT3 to enable DNA binding at SIE and APRE elements.","evidence":"Anti-STAT3 immunoprecipitation, tyrosine phosphorylation assay, gel-shift DNA binding","pmids":["7876144"],"confidence":"Medium","gaps":["Did not identify the kinase coupling GH receptor to STAT3","Single-lab DNA-binding inference of in vivo target occupancy"]},{"year":1997,"claim":"Showed that signal duration is ligand-encoded, with HGF/SF producing delayed sustained STAT3 activation versus transient IL-6 activation in hepatocytes.","evidence":"Kinetic transcription factor activation assays in primary hepatocytes and HepG2 cells","pmids":["9094433"],"confidence":"Medium","gaps":["Mechanism generating sustained versus transient kinetics not defined","Downstream target genes distinguishing the two kinetics not identified"]},{"year":1999,"claim":"Demonstrated that constitutive STAT3 activity is by itself oncogenic, establishing causality between STAT3 activation and transformation.","evidence":"SH2-domain cysteine substitution (Stat3-C), dimerization/DNA-binding/reporter assays, soft agar and nude mouse xenograft","pmids":["10458605"],"confidence":"High","gaps":["Did not enumerate the transformation-driving target genes","Engineered mutant rather than naturally occurring tumor lesion"]},{"year":2000,"claim":"Defined a physiological in vivo requirement for STAT3 in tissue remodeling, showing it initiates epithelial apoptosis during mammary involution.","evidence":"Mammary-epithelium-specific lox/Cre conditional knockout, involution and apoptosis assays","pmids":["10959419"],"confidence":"High","gaps":["Pro-apoptotic effector genes downstream of STAT3 in involution not fully resolved","Tissue-specific finding may not generalize"]},{"year":2002,"claim":"Placed STAT3 in developmental morphogenesis, showing maternal Wnt/beta-catenin activates Stat3 to drive gastrulation cell movements without altering fate.","evidence":"Dominant-negative Stat3, cell tracing, transplantation for cell-autonomy in zebrafish","pmids":["11879641"],"confidence":"High","gaps":["Molecular link from Wnt/beta-catenin to Stat3 activation undefined","Effector genes mediating migration versus convergence not identified"]},{"year":2003,"claim":"Resolved STAT3 nucleocytoplasmic shuttling, identifying a post-stimulation NES and basal NES elements supporting phosphorylation-independent CRM1-dependent export.","evidence":"Leptomycin B treatment, NES mutagenesis, subcellular localization","pmids":["12588893"],"confidence":"High","gaps":["Import machinery and karyopherins not mapped","Functional role of basal unphosphorylated nuclear STAT3 unresolved"]},{"year":2003,"claim":"Identified transcriptional repression of STAT3 via a corepressor, showing Tip60 binds STAT3 and recruits HDAC7 to silence STAT3 target genes.","evidence":"Endogenous Co-IP, reporter assays, siRNA/overexpression, c-myc readout","pmids":["12551922"],"confidence":"Medium","gaps":["Genome-wide scope of Tip60/HDAC7 repression unknown","Single-lab; reciprocal validation limited"]},{"year":2004,"claim":"Expanded the STAT3 interactome to modulators of its activity through STRA13 binding to phosphorylated STAT3 and PIAS3 redistribution from MITF to STAT3.","evidence":"Yeast two-hybrid, GST pulldown/Co-IP with phospho-STAT3, reporter and apoptosis assays; Co-IP and gene expression in MITF-mutant cells","pmids":["15223310","15572665"],"confidence":"Medium","gaps":["Physiological contexts where these interactions dominate unclear","Direct versus indirect effects on STAT3 targets not fully separated"]},{"year":2005,"claim":"Established STAT3 as a transcriptional repressor of p53, linking oncogenic STAT3 to apoptosis evasion.","evidence":"ChIP of in vivo binding, p53 promoter mutagenesis, STAT3 knockdown with p53/apoptosis readout","pmids":["16107692"],"confidence":"High","gaps":["Cofactors mediating repression at the p53 promoter not identified","Partial abrogation by single-site mutation implies additional elements"]},{"year":2005,"claim":"Revealed a transcription-independent cytoplasmic function, showing unphosphorylated STAT3 binds stathmin to promote microtubule polymerization and migration.","evidence":"Co-IP/pulldown with stathmin, microtubule polymerization and migration assays","pmids":["16835434"],"confidence":"Medium","gaps":["Structural basis of STAT3-stathmin binding undefined","In vivo relevance to metastasis not established"]},{"year":2005,"claim":"Showed that productive IL-6/STAT3 signaling requires endocytic trafficking, with phosphorylated STAT3 associating with early endosomes.","evidence":"Fractionation, EM, immunofluorescence, dominant-negative/active endocytic regulators with STAT3 reporter","pmids":["16407171"],"confidence":"High","gaps":["Endosomal scaffold tethering STAT3 not identified","Whether endosomal compartment is the site of phosphorylation unresolved"]},{"year":2005,"claim":"Defined a nuclear serine kinase input, showing ZIP kinase specifically phosphorylates STAT3 Ser727 to enhance transcription.","evidence":"Co-IP, in vitro kinase assay with phospho-Ser727 detection, siRNA, reporter assay","pmids":["16219639"],"confidence":"Medium","gaps":["Genome-wide Ser727-dependent target set not defined","Single-lab specificity claim among STATs"]},{"year":2007,"claim":"Identified a second negative regulator, KAP1/TIF1beta, that binds STAT3 and limits IL-6-driven transcription and nuclear pSer727-STAT3 accumulation.","evidence":"Yeast two-hybrid, endogenous Co-IP, siRNA, reporter and nuclear pSer727 immunostaining","pmids":["18037959"],"confidence":"Medium","gaps":["Mechanism by which KAP1 controls pSer727 levels unresolved","Direct versus indirect repression not separated"]},{"year":2008,"claim":"Distinguished pathway-specific STAT3 functions, defining a JAK2/STAT2/STAT3 axis required for myogenic differentiation separate from a proliferative JAK1/STAT1/STAT3 pathway.","evidence":"siRNA and JAK2 small-molecule inhibition, differentiation assays, qPCR of MyoD/MEF2/IGF2/HGF","pmids":["18835816"],"confidence":"Medium","gaps":["Direct STAT3 occupancy at the differentiation target genes not shown","Mechanism partitioning STAT3 between the two axes unclear"]},{"year":2010,"claim":"Uncovered a self-amplifying circuit, with STAT3 transactivating S1PR1 which in turn upregulates JAK2/IL-6 to sustain persistent STAT3 activation in cancer.","evidence":"ChIP, S1PR1 silencing in tumor and immune cells, xenograft growth/metastasis, JAK2 activity assay","pmids":["21102457"],"confidence":"High","gaps":["Quantitative thresholds sustaining the loop not defined","Tissue contexts where the loop is dispensable unknown"]},{"year":2012,"claim":"Characterized a direct chaperone interaction, showing Hsp90beta binds STAT3 in a manner requiring an intact DNA-binding domain.","evidence":"Surface plasmon resonance of recombinant proteins, RR414/417A mutagenesis, oligonucleotide pulldown, confocal colocalization","pmids":["22271514"],"confidence":"Medium","gaps":["Functional consequence of Hsp90beta binding for STAT3 stability/activity not established","Single-lab; in vivo relevance untested"]},{"year":2014,"claim":"Discovered a noncanonical activation mode, with GSK-3alpha/beta dually phosphorylating Thr714/Ser727 to drive gene induction independently of Tyr705 upon EGFR/PAR-1 co-activation.","evidence":"Quantitative LC-MS/MS, Thr714/Ser727 mutagenesis, GSK-3alpha/beta depletion, reporter assay, clinical tissue comparison","pmids":["24615012"],"confidence":"High","gaps":["Target genes specifically driven by the dual phosphoform not enumerated","Structural effect of dual phosphorylation on STAT3 not resolved"]},{"year":2015,"claim":"Defined STAT3 antagonism of TGF-beta, showing activated STAT3 binds Smad3 and blocks Smad3-Smad4 complex formation and DNA binding.","evidence":"In vivo/in vitro Co-IP, domain mapping, Smad3-Smad4 disruption assay, STAT3 knockdown with TGF-beta phenotype readouts","pmids":["26616859"],"confidence":"High","gaps":["Stoichiometry and structural interface of the STAT3-Smad3 complex undefined","Crosstalk balance in normal tissue not addressed"]},{"year":2018,"claim":"Established transcriptional control of STAT3 levels, identifying ZNF341 as a direct activator of the STAT3 promoter whose loss causes an AD-HIES-like immunodeficiency.","evidence":"Promoter binding/luciferase assays, ZNF341 mutant translocation, patient cells, STAT3 mRNA/protein quantification in consanguineous families","pmids":["29907690"],"confidence":"High","gaps":["Other transcriptional regulators of STAT3 not mapped","Mechanism connecting reduced STAT3 to Th17 loss only partially defined"]},{"year":2022,"claim":"Linked STAT3 to epigenetic remodeling, showing a vitamin D-induced VDR-pSTAT3-TET2 complex drives DNA demethylation establishing tolerogenic dendritic cells.","evidence":"Co-IP of trimeric complex, JAK2 inhibition, DNA methylation analysis, DC tolerogenesis assay","pmids":["35045292"],"confidence":"Medium","gaps":["Genome-wide demethylation sites dependent on the complex not mapped","Single-lab; direct ternary complex stoichiometry unconfirmed"]},{"year":2023,"claim":"Defined an antiviral restraint function, showing RIG-I/MAVS/Syk-driven STAT3 Y705 phosphorylation limits excessive type I/III interferon during influenza A infection.","evidence":"STAT3-Y705F knockin mice, IAV infection, IFN measurement, IFNAR1/IFNLR1 epistatic rescue, viral load","pmids":["37440406"],"confidence":"High","gaps":["Direct STAT3 target genes repressing IFN not enumerated","Mechanism of IL-6-independent Y705 phosphorylation not fully resolved"]},{"year":null,"claim":"How the diverse STAT3 inputs (tyrosine versus multi-serine/threonine phosphoforms, cofactor occupancy, endosomal localization) are integrated into context-specific transcriptional and non-transcriptional outputs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking distinct phosphoforms to specific gene programs","Determinants selecting transcriptional versus cytoskeletal/mitochondrial functions undefined","Structural basis of corepressor versus coactivator switching unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,9,15,19]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,2,9,16]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5,10]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,9,12,13]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,9,15,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,20,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,9,15,17]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,14,22]}],"complexes":["gp130/JAK1-STAT3 receptor complex","VDR-pSTAT3-TET2 complex"],"partners":["IL6ST","JAK1","SMAD3","STMN1","HSP90AB1","KAP1","PIAS3","DAPK3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P40763","full_name":"Signal transducer and activator of transcription 3","aliases":["Acute-phase response factor"],"length_aa":770,"mass_kda":88.1,"function":"Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors (PubMed:10688651, PubMed:12359225, PubMed:12873986, PubMed:15194700, PubMed:15653507, PubMed:16285960, PubMed:17344214, PubMed:18242580, PubMed:18782771, PubMed:22306293, PubMed:23084476, PubMed:28262505, PubMed:32929201, PubMed:38404237). Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:15653507, PubMed:16285960, PubMed:17344214, PubMed:18782771, PubMed:28262505, PubMed:32929201). May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:12873986). Upon activation of IL6ST/gp130 signaling by interleukin-6 (IL6), binds to the IL6-responsive elements identified in the promoters of various acute-phase protein genes (PubMed:12359225). Activated by IL31 through IL31RA (PubMed:15194700). Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acetylation promotes its transcription activity and cell differentiation while deacetylation and oxidation of lysine residues by LOXL3 inhibits differentiation (PubMed:28065600, PubMed:28262505). Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1 (PubMed:17344214). Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transctivating BIRC5 expression under LEP activation (PubMed:18242580). Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity (PubMed:23084476). Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity). Following JAK/STAT signaling activation and as part of a complex with NFATC3 and NFATC4, binds to the alpha-beta E4 promoter region of CRYAB and activates transcription in cardiomyocytes (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P40763/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/STAT3","classification":"Not Classified","n_dependent_lines":40,"n_total_lines":1208,"dependency_fraction":0.033112582781456956},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/STAT3","total_profiled":1310},"omim":[{"mim_id":"621547","title":"ZDHHC PALMITOYLTRANSFERASE 4; ZDHHC4","url":"https://www.omim.org/entry/621547"},{"mim_id":"621509","title":"G PROTEIN-COUPLED RECEPTOR 160; GPR160","url":"https://www.omim.org/entry/621509"},{"mim_id":"621405","title":"IMMUNODEFICIENCY 134 (EPSTEIN-BARR VIRUS-SPECIFIC); IMD134","url":"https://www.omim.org/entry/621405"},{"mim_id":"621321","title":"KIAA0087 LONG NONCODING RNA; KIAA0087","url":"https://www.omim.org/entry/621321"},{"mim_id":"621096","title":"IMMUNODEFICIENCY 132B; IMD132B","url":"https://www.omim.org/entry/621096"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/STAT3"},"hgnc":{"alias_symbol":["APRF"],"prev_symbol":[]},"alphafold":{"accession":"P40763","domains":[{"cath_id":"1.10.532.10","chopping":"2-96","consensus_level":"high","plddt":90.4665,"start":2,"end":96},{"cath_id":"1.20.1050.20","chopping":"143-184_197-317","consensus_level":"medium","plddt":94.7467,"start":143,"end":317},{"cath_id":"2.60.40.630","chopping":"329-417_431-497","consensus_level":"medium","plddt":91.4161,"start":329,"end":497},{"cath_id":"3.30.505.10","chopping":"503-685","consensus_level":"medium","plddt":91.7653,"start":503,"end":685}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P40763","model_url":"https://alphafold.ebi.ac.uk/files/AF-P40763-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P40763-F1-predicted_aligned_error_v6.png","plddt_mean":84.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=STAT3","jax_strain_url":"https://www.jax.org/strain/search?query=STAT3"},"sequence":{"accession":"P40763","fasta_url":"https://rest.uniprot.org/uniprotkb/P40763.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P40763/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P40763"}},"corpus_meta":[{"pmid":"10458605","id":"PMC_10458605","title":"Stat3 as an oncogene.","date":"1999","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10458605","citation_count":2504,"is_preprint":false},{"pmid":"32972405","id":"PMC_32972405","title":"Targeting STAT3 in Cancer Immunotherapy.","date":"2020","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32972405","citation_count":872,"is_preprint":false},{"pmid":"8272872","id":"PMC_8272872","title":"Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8272872","citation_count":728,"is_preprint":false},{"pmid":"25951043","id":"PMC_25951043","title":"The role of STAT3 in autophagy.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25951043","citation_count":445,"is_preprint":false},{"pmid":"19053881","id":"PMC_19053881","title":"Targeting STAT3 in cancer: how successful are we?","date":"2009","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/19053881","citation_count":346,"is_preprint":false},{"pmid":"21102457","id":"PMC_21102457","title":"STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.","date":"2010","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21102457","citation_count":342,"is_preprint":false},{"pmid":"16107692","id":"PMC_16107692","title":"Role of Stat3 in regulating p53 expression and function.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16107692","citation_count":332,"is_preprint":false},{"pmid":"21441118","id":"PMC_21441118","title":"STAT3 signaling: anticancer strategies and challenges.","date":"2011","source":"Molecular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/21441118","citation_count":329,"is_preprint":false},{"pmid":"15930886","id":"PMC_15930886","title":"Targeting Stat3 in cancer therapy.","date":"2005","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/15930886","citation_count":248,"is_preprint":false},{"pmid":"37081874","id":"PMC_37081874","title":"Advances in the role of STAT3 in macrophage polarization.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37081874","citation_count":231,"is_preprint":false},{"pmid":"15986140","id":"PMC_15986140","title":"Targeting STAT3 affects melanoma on multiple fronts.","date":"2005","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15986140","citation_count":231,"is_preprint":false},{"pmid":"29316631","id":"PMC_29316631","title":"Psoriasis: A STAT3-Centric View.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29316631","citation_count":195,"is_preprint":false},{"pmid":"25825152","id":"PMC_25825152","title":"STAT3 the oncogene - still eluding therapy?","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25825152","citation_count":173,"is_preprint":false},{"pmid":"7876144","id":"PMC_7876144","title":"Activation of acute phase response factor (APRF)/Stat3 transcription factor by growth hormone.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7876144","citation_count":169,"is_preprint":false},{"pmid":"32987855","id":"PMC_32987855","title":"Redox Regulation of STAT1 and STAT3 Signaling.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32987855","citation_count":168,"is_preprint":false},{"pmid":"32702499","id":"PMC_32702499","title":"STAT3: A key regulator in liver fibrosis.","date":"2020","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32702499","citation_count":162,"is_preprint":false},{"pmid":"29782972","id":"PMC_29782972","title":"STAT3 and apoptosis challenges in cancer.","date":"2018","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/29782972","citation_count":156,"is_preprint":false},{"pmid":"11879641","id":"PMC_11879641","title":"Stat3 Controls Cell Movements during Zebrafish Gastrulation.","date":"2002","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/11879641","citation_count":148,"is_preprint":false},{"pmid":"29873274","id":"PMC_29873274","title":"STAT3: a multifaceted oncoprotein.","date":"2018","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29873274","citation_count":147,"is_preprint":false},{"pmid":"11987152","id":"PMC_11987152","title":"Stat3 activation in prostatic carcinomas.","date":"2002","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/11987152","citation_count":126,"is_preprint":false},{"pmid":"33382511","id":"PMC_33382511","title":"STAT3 and its targeting inhibitors in osteosarcoma.","date":"2020","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/33382511","citation_count":121,"is_preprint":false},{"pmid":"29907690","id":"PMC_29907690","title":"ZNF341 controls STAT3 expression and thereby immunocompetence.","date":"2018","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29907690","citation_count":121,"is_preprint":false},{"pmid":"18835816","id":"PMC_18835816","title":"JAK2/STAT2/STAT3 are required for myogenic differentiation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18835816","citation_count":121,"is_preprint":false},{"pmid":"27019635","id":"PMC_27019635","title":"Mitochondrial Stat3, the Need for Design Thinking.","date":"2016","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27019635","citation_count":120,"is_preprint":false},{"pmid":"22891351","id":"PMC_22891351","title":"STAT3 negatively regulates thyroid tumorigenesis.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22891351","citation_count":116,"is_preprint":false},{"pmid":"12588893","id":"PMC_12588893","title":"Regulation of Stat3 nuclear export.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12588893","citation_count":115,"is_preprint":false},{"pmid":"17305481","id":"PMC_17305481","title":"Small molecule inhibitors of Stat3 signaling pathway.","date":"2007","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/17305481","citation_count":114,"is_preprint":false},{"pmid":"22348200","id":"PMC_22348200","title":"PI3K and STAT3: a new alliance.","date":"2011","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/22348200","citation_count":111,"is_preprint":false},{"pmid":"23688441","id":"PMC_23688441","title":"The role of Stat3 in glioblastoma multiforme.","date":"2013","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/23688441","citation_count":105,"is_preprint":false},{"pmid":"24995504","id":"PMC_24995504","title":"STAT3 in Cancer-Friend or Foe?","date":"2014","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/24995504","citation_count":103,"is_preprint":false},{"pmid":"24058777","id":"PMC_24058777","title":"STAT3 signaling in pulmonary arterial hypertension.","date":"2012","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24058777","citation_count":101,"is_preprint":false},{"pmid":"35779691","id":"PMC_35779691","title":"STAT3-mediated ferroptosis is involved in ulcerative colitis.","date":"2022","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35779691","citation_count":99,"is_preprint":false},{"pmid":"19601808","id":"PMC_19601808","title":"STAT3 regulation of glioblastoma pathogenesis.","date":"2009","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19601808","citation_count":99,"is_preprint":false},{"pmid":"12551922","id":"PMC_12551922","title":"Tip60 is a co-repressor for STAT3.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12551922","citation_count":97,"is_preprint":false},{"pmid":"24058788","id":"PMC_24058788","title":"STAT3 inhibitors for cancer therapy: Have all roads been explored?","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24058788","citation_count":96,"is_preprint":false},{"pmid":"17610223","id":"PMC_17610223","title":"Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis.","date":"2007","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17610223","citation_count":95,"is_preprint":false},{"pmid":"28686955","id":"PMC_28686955","title":"Targeting STAT3 with silibinin to improve cancer therapeutics.","date":"2017","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28686955","citation_count":95,"is_preprint":false},{"pmid":"31557897","id":"PMC_31557897","title":"STAT3 and STAT5 Activation in Solid Cancers.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31557897","citation_count":92,"is_preprint":false},{"pmid":"17073743","id":"PMC_17073743","title":"STAT3-mediated anti-inflammatory signalling.","date":"2006","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17073743","citation_count":90,"is_preprint":false},{"pmid":"27344294","id":"PMC_27344294","title":"Expression of STAT3 in Prostate Cancer Metastases.","date":"2016","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/27344294","citation_count":90,"is_preprint":false},{"pmid":"26616859","id":"PMC_26616859","title":"STAT3 selectively interacts with Smad3 to antagonize TGF-β signalling.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26616859","citation_count":90,"is_preprint":false},{"pmid":"33849593","id":"PMC_33849593","title":"STAT3 phosphorylation in central leptin resistance.","date":"2021","source":"Nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33849593","citation_count":88,"is_preprint":false},{"pmid":"30943069","id":"PMC_30943069","title":"Targeting STAT3 signaling in kidney disease.","date":"2019","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30943069","citation_count":87,"is_preprint":false},{"pmid":"20407820","id":"PMC_20407820","title":"STAT3 and cardiac remodeling.","date":"2011","source":"Heart failure reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20407820","citation_count":86,"is_preprint":false},{"pmid":"10959419","id":"PMC_10959419","title":"The role of Stat3 in apoptosis and mammary gland involution. Conditional deletion of Stat3.","date":"2000","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/10959419","citation_count":86,"is_preprint":false},{"pmid":"22834702","id":"PMC_22834702","title":"Targeting STAT3 in gastric cancer.","date":"2012","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/22834702","citation_count":83,"is_preprint":false},{"pmid":"31817042","id":"PMC_31817042","title":"Direct Targeting Options for STAT3 and STAT5 in Cancer.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31817042","citation_count":76,"is_preprint":false},{"pmid":"32518375","id":"PMC_32518375","title":"GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32518375","citation_count":76,"is_preprint":false},{"pmid":"25893308","id":"PMC_25893308","title":"IGFBP2 potentiates nuclear EGFR-STAT3 signaling.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25893308","citation_count":72,"is_preprint":false},{"pmid":"19935868","id":"PMC_19935868","title":"Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein.","date":"2009","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/19935868","citation_count":72,"is_preprint":false},{"pmid":"31861597","id":"PMC_31861597","title":"STAT3 Activation and Oncogenesis in Lymphoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31861597","citation_count":70,"is_preprint":false},{"pmid":"16835434","id":"PMC_16835434","title":"Touched and moved by STAT3.","date":"2006","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/16835434","citation_count":69,"is_preprint":false},{"pmid":"26413424","id":"PMC_26413424","title":"Role of STAT3 in lung cancer.","date":"2015","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/26413424","citation_count":69,"is_preprint":false},{"pmid":"29140406","id":"PMC_29140406","title":"Smad3-STAT3 crosstalk in pathophysiological contexts.","date":"2018","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/29140406","citation_count":68,"is_preprint":false},{"pmid":"30031681","id":"PMC_30031681","title":"STAT3 isoforms: Alternative fates in cancer?","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/30031681","citation_count":68,"is_preprint":false},{"pmid":"18037959","id":"PMC_18037959","title":"Physical and functional interactions between STAT3 and KAP1.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18037959","citation_count":65,"is_preprint":false},{"pmid":"16407171","id":"PMC_16407171","title":"Membrane-associated STAT3 and PY-STAT3 in the cytoplasm.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16407171","citation_count":64,"is_preprint":false},{"pmid":"35879773","id":"PMC_35879773","title":"STAT3-mediated osteogenesis and osteoclastogenesis in osteoporosis.","date":"2022","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/35879773","citation_count":61,"is_preprint":false},{"pmid":"27269970","id":"PMC_27269970","title":"Mitochondrial STAT3: Powering up a potent factor.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/27269970","citation_count":60,"is_preprint":false},{"pmid":"21619876","id":"PMC_21619876","title":"The R(h)oads to Stat3: Stat3 activation by the Rho GTPases.","date":"2011","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21619876","citation_count":60,"is_preprint":false},{"pmid":"28100038","id":"PMC_28100038","title":"TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28100038","citation_count":59,"is_preprint":false},{"pmid":"24705981","id":"PMC_24705981","title":"STAT3 inhibitors: finding a home in lymphoma and leukemia.","date":"2014","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/24705981","citation_count":58,"is_preprint":false},{"pmid":"15223310","id":"PMC_15223310","title":"STRA13 interacts with STAT3 and modulates transcription of STAT3-dependent targets.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15223310","citation_count":55,"is_preprint":false},{"pmid":"27764801","id":"PMC_27764801","title":"FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27764801","citation_count":55,"is_preprint":false},{"pmid":"15572665","id":"PMC_15572665","title":"Interplay between MITF, PIAS3, and STAT3 in mast cells and melanocytes.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15572665","citation_count":55,"is_preprint":false},{"pmid":"16219639","id":"PMC_16219639","title":"Physical and functional interactions between STAT3 and ZIP kinase.","date":"2005","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16219639","citation_count":54,"is_preprint":false},{"pmid":"37620559","id":"PMC_37620559","title":"Perspective: mitochondrial STAT3 in cardioprotection.","date":"2023","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/37620559","citation_count":53,"is_preprint":false},{"pmid":"28031890","id":"PMC_28031890","title":"Role of STAT3 pathway in genitourinary tumors.","date":"2015","source":"Future science OA","url":"https://pubmed.ncbi.nlm.nih.gov/28031890","citation_count":52,"is_preprint":false},{"pmid":"25105066","id":"PMC_25105066","title":"Effects of JAK2-STAT3 signaling after cerebral insults.","date":"2014","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/25105066","citation_count":52,"is_preprint":false},{"pmid":"33371351","id":"PMC_33371351","title":"STAT3 and p53: Dual Target for Cancer Therapy.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/33371351","citation_count":51,"is_preprint":false},{"pmid":"33003453","id":"PMC_33003453","title":"Perspectives Regarding the Intersections between STAT3 and Oxidative Metabolism in Cancer.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33003453","citation_count":51,"is_preprint":false},{"pmid":"28433699","id":"PMC_28433699","title":"EGFR-mediated apoptosis via STAT3.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28433699","citation_count":49,"is_preprint":false},{"pmid":"32201498","id":"PMC_32201498","title":"STAT3 roles in viral infection: antiviral or proviral?","date":"2018","source":"Future virology","url":"https://pubmed.ncbi.nlm.nih.gov/32201498","citation_count":49,"is_preprint":false},{"pmid":"23827176","id":"PMC_23827176","title":"The Stat3 paradox: a killer and an oncogene.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23827176","citation_count":48,"is_preprint":false},{"pmid":"20951825","id":"PMC_20951825","title":"STAT3 in tissue fibrosis: is there a role in the lung?","date":"2010","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20951825","citation_count":48,"is_preprint":false},{"pmid":"35045292","id":"PMC_35045292","title":"Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35045292","citation_count":47,"is_preprint":false},{"pmid":"20667852","id":"PMC_20667852","title":"PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.","date":"2010","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20667852","citation_count":47,"is_preprint":false},{"pmid":"31511651","id":"PMC_31511651","title":"CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31511651","citation_count":46,"is_preprint":false},{"pmid":"21618433","id":"PMC_21618433","title":"Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.","date":"2011","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/21618433","citation_count":46,"is_preprint":false},{"pmid":"37440406","id":"PMC_37440406","title":"STAT3 regulates antiviral immunity by suppressing excessive interferon signaling.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37440406","citation_count":45,"is_preprint":false},{"pmid":"27017613","id":"PMC_27017613","title":"Understanding STAT3 signaling in cardiac ischemia.","date":"2016","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27017613","citation_count":45,"is_preprint":false},{"pmid":"32733808","id":"PMC_32733808","title":"STAT3 Contributes to Radioresistance in Cancer.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32733808","citation_count":44,"is_preprint":false},{"pmid":"9094433","id":"PMC_9094433","title":"Hepatocyte growth factor/scatter factor (HGF/SF) signals via the STAT3/APRF transcription factor in human hepatoma cells and hepatocytes.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9094433","citation_count":44,"is_preprint":false},{"pmid":"36578083","id":"PMC_36578083","title":"KPNA2 promotes angiogenesis by regulating STAT3 phosphorylation.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36578083","citation_count":42,"is_preprint":false},{"pmid":"32872659","id":"PMC_32872659","title":"STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32872659","citation_count":42,"is_preprint":false},{"pmid":"31671769","id":"PMC_31671769","title":"Targeting STAT3 in Cancer with Nucleotide Therapeutics.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31671769","citation_count":42,"is_preprint":false},{"pmid":"36055997","id":"PMC_36055997","title":"Nintedanib induces senolytic effect via STAT3 inhibition.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36055997","citation_count":41,"is_preprint":false},{"pmid":"24615012","id":"PMC_24615012","title":"Signal integration and gene induction by a functionally distinct STAT3 phosphoform.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24615012","citation_count":39,"is_preprint":false},{"pmid":"30822557","id":"PMC_30822557","title":"STAT3beta, a distinct isoform from STAT3.","date":"2019","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30822557","citation_count":38,"is_preprint":false},{"pmid":"39918020","id":"PMC_39918020","title":"Importance of STAT3 signaling in preeclampsia (Review).","date":"2025","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39918020","citation_count":38,"is_preprint":false},{"pmid":"30395230","id":"PMC_30395230","title":"STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.","date":"2019","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30395230","citation_count":37,"is_preprint":false},{"pmid":"31566109","id":"PMC_31566109","title":"Global transcriptional regulation of STAT3- and MYC-mediated sepsis-induced ARDS.","date":"2019","source":"Therapeutic advances in respiratory disease","url":"https://pubmed.ncbi.nlm.nih.gov/31566109","citation_count":37,"is_preprint":false},{"pmid":"36814203","id":"PMC_36814203","title":"FANCD2 inhibits ferroptosis by regulating the JAK2/STAT3 pathway in osteosarcoma.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36814203","citation_count":36,"is_preprint":false},{"pmid":"22211709","id":"PMC_22211709","title":"Stat3: linking inflammation to (gastrointestinal) tumourigenesis.","date":"2012","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22211709","citation_count":34,"is_preprint":false},{"pmid":"22271514","id":"PMC_22271514","title":"STAT3 interacts directly with Hsp90.","date":"2012","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/22271514","citation_count":33,"is_preprint":false},{"pmid":"22197944","id":"PMC_22197944","title":"STAT3 genotypic variation and cellular STAT3 activation and colon leukocyte recruitment in pediatric Crohn disease.","date":"2012","source":"Journal of pediatric gastroenterology and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/22197944","citation_count":33,"is_preprint":false},{"pmid":"32142763","id":"PMC_32142763","title":"Silencing of p68 and STAT3 synergistically diminishes cancer progression.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32142763","citation_count":32,"is_preprint":false},{"pmid":"39117533","id":"PMC_39117533","title":"Targeting the STAT3 pathway with STAT3 degraders.","date":"2024","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39117533","citation_count":31,"is_preprint":false},{"pmid":"24470976","id":"PMC_24470976","title":"JAK-STAT3 and somatic cell reprogramming.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24470976","citation_count":31,"is_preprint":false},{"pmid":"30256396","id":"PMC_30256396","title":"Stat3 activation is critical for pluripotency maintenance.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30256396","citation_count":31,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":40802,"output_tokens":6275,"usd":0.108266,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15156,"output_tokens":6666,"usd":0.121215,"stage2_stop_reason":"end_turn"},"total_usd":0.229481,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"APRF (STAT3) associates physically with both the IL-6 signal transducer gp130 and the Jak1 protein kinase upon stimulation by IL-6-family cytokines, and undergoes tyrosine phosphorylation in this complex, establishing that Jak family kinases participate in IL-6 signaling via STAT3.\",\n      \"method\": \"Co-immunoprecipitation, tyrosine phosphorylation assays, DNA-binding assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP of endogenous proteins, replicated across multiple cytokines and cell types, foundational paper with multiple orthogonal methods\",\n      \"pmids\": [\"8272872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Growth hormone (GH) activates STAT3 by promoting tyrosine phosphorylation of STAT3, enabling it to bind DNA elements (SIE in c-fos promoter and APRE in alpha2-macroglobulin promoter), demonstrating GH signals through multiple STAT proteins including STAT3.\",\n      \"method\": \"Immunoprecipitation with anti-STAT3 antibodies, tyrosine phosphorylation assay, gel shift/DNA-binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tyrosine phosphorylation and DNA-binding assays in single lab with two orthogonal methods\",\n      \"pmids\": [\"7876144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Substitution of two cysteine residues within the C-terminal loop of the STAT3 SH2 domain (Stat3-C) produces a molecule that dimerizes spontaneously, binds DNA constitutively, activates transcription, and causes cellular transformation (soft agar colony formation, nude mouse tumor formation), demonstrating that constitutively active STAT3 alone is sufficient to mediate oncogenic transformation.\",\n      \"method\": \"Site-directed mutagenesis, dimerization assay, DNA-binding assay, transcriptional reporter assay, soft agar colony formation, nude mouse xenograft\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — active-site mutagenesis with multiple functional readouts (in vitro dimerization, DNA binding, transcription, transformation, tumor formation) in a single rigorous study\",\n      \"pmids\": [\"10458605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"HGF/SF activates STAT3 in human hepatocytes and hepatoma cells (HepG2) via the JAK/STAT pathway; unlike IL-6-induced rapid and transient STAT3 activation, HGF/SF-induced STAT3 activation is delayed (5–7 h) and sustained (up to 28 h).\",\n      \"method\": \"Transcription factor activation assay, kinetic analysis in primary hepatocytes and HepG2 cells\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct STAT3 activation assays in two cell types with defined kinetics, single lab\",\n      \"pmids\": [\"9094433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Zebrafish Stat3 is activated on the dorsal side by the maternal Wnt/beta-catenin pathway and is required cell-autonomously for anterior migration of dorsal mesendodermal cells and non-cell-autonomously for convergence of paraxial cells during gastrulation; loss of Stat3 causes abnormal gastrulation movements without defects in early cell fate specification.\",\n      \"method\": \"Dominant-negative Stat3 expression, cell tracing, transplantation experiments, time-course analysis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Wnt/beta-catenin upstream of Stat3), cell-autonomous vs non-autonomous dissection via transplantation, multiple orthogonal methods\",\n      \"pmids\": [\"11879641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"STAT3 nuclear export is regulated by multiple nuclear export signal (NES) elements: NES Stat3(306-318) mediates post-stimulation export, while Stat3(404-414) and Stat3(524-535) regulate basal nuclear export. LMB (leptomycin B) blocks post-stimulation export and also causes nuclear accumulation of unphosphorylated Stat3 in resting cells, revealing a tyrosine phosphorylation-independent basal nuclear export pathway.\",\n      \"method\": \"Leptomycin B treatment, NES mutagenesis, subcellular fractionation/localization assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NES mutagenesis combined with pharmacological blockade and subcellular localization, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"12588893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Tip60 (a histone acetyltransferase) physically associates with endogenous STAT3 and represses STAT3-driven transcription by recruiting HDAC7 through its N-terminal zinc finger region; overexpression of Tip60 abrogates IL-9-induced STAT3-dependent c-myc expression.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, reporter gene assay, siRNA/overexpression, endogenous target gene (c-myc) measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous Co-IP plus functional transcription assays, single lab\",\n      \"pmids\": [\"12551922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"STRA13 binds predominantly to phosphorylated (active) STAT3α and STAT3β isoforms via its HLH and C-terminal regions, activates transcription from STAT-dependent elements, and modulates STAT3-regulated pro-apoptotic Fas gene promoter activity; co-expression of STRA13 with STAT3β alleviates STRA13's pro-apoptotic effect.\",\n      \"method\": \"Yeast two-hybrid screening, GST pulldown/Co-IP with phosphorylated STAT3, reporter gene assay, apoptosis assay\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid identification confirmed by binding assay with phosphorylated STAT3, functional transcriptional and apoptosis readouts, single lab\",\n      \"pmids\": [\"15223310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In mast cells and melanocytes stimulated via gp130 or c-Kit receptors, cytokine-induced phosphorylation of MITF at S409 causes dissociation of PIAS3 from MITF and its re-association with STAT3, thereby modulating STAT3-dependent gene expression; cells from MITF(di/di) mice (lacking the PIAS3-binding Zip domain of MITF) show downregulation of genes regulated by either MITF or STAT3.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, mRNA expression analysis in MITF mutant cells, cell stimulation via gp130/c-Kit\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing dynamic PIAS3 redistribution between MITF and STAT3 with functional gene expression readout in genetic model, single lab\",\n      \"pmids\": [\"15572665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Oncogenic Stat3 binds to the p53 gene promoter in vitro and in vivo (ChIP), and site-specific mutation of a Stat3 DNA-binding site in the p53 promoter partially abrogates Stat3-induced inhibition; blocking Stat3 in cancer cells upregulates p53 expression leading to p53-mediated apoptosis, placing Stat3 as a transcriptional repressor of p53.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter reporter assay with site-directed mutagenesis, Stat3 inhibition/knockdown with p53 expression and apoptosis readout\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP showing in vivo binding plus promoter mutagenesis abrogating repression plus functional knockdown rescue, multiple orthogonal methods in single study\",\n      \"pmids\": [\"16107692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cytoplasmic (non-tyrosine-phosphorylated) STAT3 mediates cell migration by associating with stathmin, potentiating microtubule polymerization; this disrupts the stathmin-microtubule interaction and promotes cell movement.\",\n      \"method\": \"Co-immunoprecipitation/pulldown of STAT3 with stathmin, microtubule polymerization assay, cell migration assay\",\n      \"journal\": \"Science's STKE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying STAT3-stathmin interaction with functional microtubule polymerization and migration readout, single lab\",\n      \"pmids\": [\"16835434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"STAT3 is constitutively associated (~5%) with the early endosome fraction; after IL-6 treatment, up to two-thirds of cytoplasmic tyrosine-phosphorylated STAT3 associates with early endosomes. STAT3 transcriptional activation is inhibited by dominant-negative dynamin K44A, epsin 2a, amphiphysin A1, and clathrin light chain, but enhanced by active dynamin MxA, demonstrating that endocytic trafficking is required for productive IL-6/STAT3 signaling.\",\n      \"method\": \"Cell fractionation, electron microscopy, immunofluorescence, detergent dissection, transient transfection with dominant-negative/active endocytic regulators and STAT3-reporter luciferase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (EM, immunofluorescence, fractionation, functional reporter with dominant mutants) demonstrating endosomal STAT3 localization with functional consequence\",\n      \"pmids\": [\"16407171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ZIP kinase (ZIPK) physically interacts specifically with STAT3 (but not STAT1, STAT4, STAT5a, STAT5b, or STAT6), phosphorylates STAT3 on Ser727 in the nucleus, and enhances STAT3 transcriptional activity; siRNA knockdown of ZIPK decreases LIF- and IL-6-induced STAT3-dependent transcription.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay with phospho-Ser727 detection, siRNA knockdown, transcriptional reporter assay\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase assay identifying STAT3-Ser727 as ZIPK substrate plus Co-IP and siRNA functional validation, single lab\",\n      \"pmids\": [\"16219639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"KAP1/TIF1beta (a universal corepressor) physically associates with endogenous STAT3 in vivo; siRNA-mediated knockdown of KAP1 enhances IL-6-induced STAT3-dependent transcription and causes marked accumulation of Ser727-phosphorylated STAT3 in the nucleus, indicating KAP1 negatively regulates the IL-6/STAT3 signaling pathway.\",\n      \"method\": \"Yeast two-hybrid screening, Co-IP of endogenous proteins, siRNA knockdown, transcriptional reporter assay, nuclear pSer727-STAT3 immunostaining\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous Co-IP confirmed by functional siRNA transcription assay, single lab\",\n      \"pmids\": [\"18037959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A JAK2/STAT2/STAT3 signaling axis (distinct from the JAK1/STAT1/STAT3 proliferation pathway) is required for early myogenic differentiation; inhibition by small molecule JAK2 inhibitor or siRNA against JAK2, STAT2, or STAT3 blocks myogenic differentiation. The pro-differentiation effect is partially mediated through MyoD, MEF2, IGF2, and HGF gene regulation.\",\n      \"method\": \"siRNA knockdown of JAK2/STAT2/STAT3, small molecule JAK2 inhibitor, differentiation assays, qPCR for MyoD/MEF2/IGF2/HGF\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown and pharmacological inhibition with differentiation phenotype and target gene readouts, single lab\",\n      \"pmids\": [\"18835816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"STAT3 acts as a transcription factor for the S1PR1 gene; reciprocally, S1PR1 activates STAT3 (in part by upregulating JAK2 kinase activity) and upregulates IL-6 expression, forming a positive feedback loop that sustains persistent STAT3 activation in cancer cells. S1P-S1PR1-induced STAT3 activation is persistent, in contrast to transient IL-6-induced STAT3 activation.\",\n      \"method\": \"Chromatin immunoprecipitation, S1PR1 silencing (siRNA/shRNA) in tumor cells and immune cells, xenograft tumor growth/metastasis assay, JAK2 activity assay\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP identifying STAT3 as S1PR1 transcription factor, functional silencing in multiple contexts (tumor cells, immune cells, in vivo), mechanistic validation of JAK2 upregulation, multiple orthogonal methods\",\n      \"pmids\": [\"21102457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"STAT3 directly interacts with Hsp90β with high affinity (surface plasmon resonance of recombinant proteins); this interaction requires a functional DNA-binding domain (RR414/417); the interaction is not preferentially altered by a phosphomimetic mutation at tyrosine 705.\",\n      \"method\": \"Surface plasmon resonance spectroscopy with recombinant proteins, site-directed mutagenesis of STAT3 (RR414/417A), DNA-binding oligonucleotide pulldown, confocal colocalization in MCF7 cells\",\n      \"journal\": \"IUBMB life\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro SPR with recombinant proteins plus mutagenesis validating DNA-binding domain requirement, single lab\",\n      \"pmids\": [\"22271514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"STAT3 is simultaneously phosphorylated at Thr714 and Ser727 by GSK-3α/β to form a noncanonical phosphoform that drives STAT3-dependent gene induction independently of Tyr705 phosphorylation in response to combined EGFR and PAR-1 activation; both residues are required and depletion of GSK-3α/β is sufficient to disrupt this signal integration. Doubly phosphorylated STAT3 (but not pTyr705-STAT3) is elevated in clear-cell renal-cell carcinoma.\",\n      \"method\": \"Quantitative LC-MS/MS mass spectrometry, site-directed mutagenesis of Thr714/Ser727, GSK-3α/β depletion (siRNA), STAT3-dependent reporter assay, clinical tissue comparison\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — MS discovery of novel phosphoform confirmed by mutagenesis, kinase depletion with gene expression readout, and clinical validation; multiple orthogonal methods in single study\",\n      \"pmids\": [\"24615012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Activated STAT3 directly interacts with Smad3 in vivo and in vitro; this interaction attenuates Smad3-Smad4 complex formation and suppresses Smad3 DNA-binding ability, antagonizing TGF-β signaling. The N-terminal region of the STAT3 DNA-binding domain is responsible for the STAT3-Smad3 interaction and is indispensable for STAT3-mediated TGF-β inhibition.\",\n      \"method\": \"Co-immunoprecipitation in vivo and in vitro pulldown, STAT3/Smad3 domain mapping, Smad3-Smad4 complex disruption assay, DNA-binding assay, STAT3 knockdown with TGF-β response readouts (cell cycle arrest, apoptosis, EMT)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro and in vivo interaction confirmed, domain mapping, mechanistic disruption of Smad3-Smad4 complex, functional knockdown with multiple phenotypic readouts, multiple orthogonal methods\",\n      \"pmids\": [\"26616859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZNF341, a zinc finger transcription factor, binds to and activates the STAT3 promoter; loss-of-function mutations in ZNF341 reduce STAT3 expression and result in an AD-HIES-like immunodeficiency phenotype with decreased Th17 cells, establishing ZNF341 as a direct transcriptional regulator of STAT3 expression.\",\n      \"method\": \"Promoter binding assay (ZNF341 binding to STAT3 promoter), luciferase reporter assay, nuclear translocation analysis of mutant ZNF341, patient-derived cell characterization, STAT3 mRNA/protein quantification\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter binding by ZNF341 with transcriptional activation assay, mutagenesis showing loss of function, replicated in four consanguineous families with consistent phenotype\",\n      \"pmids\": [\"29907690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-6-independent STAT3 Y705 phosphorylation at early stages of influenza A virus (IAV) infection is dependent on the RIG-I/MAVS/Syk signaling axis; STAT3 Y705 phosphorylation restrains IAV pathogenesis by repressing excessive production of type I and III interferons. STAT3Y705F knockin mice show impaired antiviral gene expression, severe lung injury, and poor survival; knockout of IFNAR1 or IFNLR1 in STAT3Y705F mice rescues lung injury and reduces viral load.\",\n      \"method\": \"STAT3-Y705F knockin mice, IAV infection model, IFN expression measurement, genetic epistasis (IFNAR1/IFNLR1 knockout in knockin background), viral load quantification\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockin mouse model with Y705F mutation, genetic epistasis rescue by IFN receptor knockout, multiple in vivo phenotypic readouts establishing mechanistic pathway\",\n      \"pmids\": [\"37440406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VDR and phosphorylated STAT3 (phosphorylated by JAK2 specifically in response to vitamin D stimulation) interact with each other and with the DNA demethylase TET2 to form a complex that drives DNA demethylation and transcriptional activation at VDR binding sites, establishing tolerogenesis in dendritic cells; pharmacological JAK2 inhibition reverts vitamin D-induced tolerogenic properties.\",\n      \"method\": \"Co-immunoprecipitation of VDR-pSTAT3-TET2 complex, JAK2 inhibitor treatment, DNA methylation analysis, DC tolerogenesis functional assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying trimeric complex, pharmacological epistasis confirming JAK2-STAT3 requirement for tolerogenesis, single lab\",\n      \"pmids\": [\"35045292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Conditional knockout of STAT3 specifically in mammary gland epithelium (using lox/Cre system) causes decreased epithelial apoptosis and dramatic delay of mammary gland involution upon forced weaning, demonstrating that STAT3 is required for initiation of physiological apoptosis during mammary involution in vivo.\",\n      \"method\": \"Conditional gene knockout (lox/Cre), mammary gland involution assay, apoptosis quantification, STAT1/p53/p21 expression analysis\",\n      \"journal\": \"Advances in experimental medicine and biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic knockout with specific in vivo phenotypic readout (impaired apoptosis/involution), complementary pathway analysis\",\n      \"pmids\": [\"10959419\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"STAT3 is a latent cytoplasmic transcription factor that is activated by tyrosine phosphorylation (primarily at Y705) by JAK-family kinases downstream of cytokine receptors (e.g., gp130/JAK1 for IL-6-family cytokines) and growth factor receptors; upon phosphorylation it dimerizes via SH2-phosphotyrosine interactions, translocates to the nucleus via a CRM1-dependent export pathway regulated by multiple NES elements, and activates or represses target genes (including S1PR1, p53, and IFN-response genes); its activity is further modulated by Ser727 phosphorylation (by ZIPK and GSK-3α/β), non-canonical Thr714/Ser727 dual phosphorylation by GSK-3, interaction with co-repressors (Tip60/HDAC7, KAP1), direct binding to Smad3 to antagonize TGF-β signaling, cytoplasmic sequestration of stathmin to promote microtubule polymerization and cell migration, mitochondrial localization where it regulates electron transport chain activity, and transcriptional control of STAT3 expression itself by ZNF341; constitutively activating mutations in the SH2 domain (Stat3-C) are sufficient for oncogenic transformation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"STAT3 is a latent cytoplasmic transcription factor that transduces signals from cytokine and growth factor receptors to the nucleus, where it activates and represses target genes governing proliferation, apoptosis, differentiation, and migration [#0, #2]. It is recruited to the IL-6 signal transducer gp130 together with the Jak1 kinase and undergoes tyrosine phosphorylation within this complex [#0], and is similarly activated by growth hormone and HGF/SF through the JAK/STAT pathway, with HGF/SF producing delayed and sustained activation in contrast to the transient IL-6 response [#1, #3]. Productive IL-6/STAT3 signaling further requires endocytic trafficking, as tyrosine-phosphorylated STAT3 associates with early endosomes and transcriptional output depends on intact clathrin/dynamin-mediated endocytosis [#11]. Nuclear residence is controlled by multiple CRM1-dependent nuclear export signals, including a post-stimulation NES and basal NES elements that export even unphosphorylated STAT3 [#5]. Beyond canonical Tyr705 phosphorylation, STAT3 activity is tuned by Ser727 phosphorylation by ZIP kinase, which enhances transcription [#12], and by a noncanonical dual Thr714/Ser727 phosphorylation by GSK-3\\u03b1/\\u03b2 that drives gene induction independently of Tyr705 upon EGFR/PAR-1 co-activation [#17]. As a sequence-specific factor STAT3 represses the p53 promoter to restrain apoptosis [#9] and transcriptionally activates S1PR1 in a feed-forward loop with IL-6/JAK2 that sustains persistent activation in tumors [#15]. Its output is constrained by corepressors that physically associate with STAT3, including Tip60/HDAC7 and KAP1/TIF1\\u03b2 [#6, #13]. STAT3 also acts through non-transcriptional and protein-protein routes: cytoplasmic unphosphorylated STAT3 binds stathmin to promote microtubule polymerization and cell migration [#10], and activated STAT3 binds Smad3 to disrupt Smad3-Smad4 complex formation and antagonize TGF-\\u03b2 signaling [#18]. STAT3 expression itself is directly driven by the zinc-finger transcription factor ZNF341, whose loss-of-function causes an autosomal-dominant hyper-IgE syndrome-like immunodeficiency [#19]. In vivo, STAT3 is required for physiological epithelial apoptosis during mammary gland involution [#22] and for restraining excessive type I/III interferon production during influenza A infection [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established how STAT3 is activated, by showing it physically engages the gp130 receptor and Jak1 kinase upon IL-6-family cytokine stimulation and is tyrosine-phosphorylated in that complex.\",\n      \"evidence\": \"Reciprocal Co-IP of endogenous proteins, tyrosine phosphorylation and DNA-binding assays across cytokines/cell types\",\n      \"pmids\": [\"8272872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the phosphorylation site stoichiometry or dimer geometry\", \"Did not address receptors beyond the IL-6 family\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Extended the activation repertoire beyond cytokines by showing growth hormone tyrosine-phosphorylates STAT3 to enable DNA binding at SIE and APRE elements.\",\n      \"evidence\": \"Anti-STAT3 immunoprecipitation, tyrosine phosphorylation assay, gel-shift DNA binding\",\n      \"pmids\": [\"7876144\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the kinase coupling GH receptor to STAT3\", \"Single-lab DNA-binding inference of in vivo target occupancy\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showed that signal duration is ligand-encoded, with HGF/SF producing delayed sustained STAT3 activation versus transient IL-6 activation in hepatocytes.\",\n      \"evidence\": \"Kinetic transcription factor activation assays in primary hepatocytes and HepG2 cells\",\n      \"pmids\": [\"9094433\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism generating sustained versus transient kinetics not defined\", \"Downstream target genes distinguishing the two kinetics not identified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated that constitutive STAT3 activity is by itself oncogenic, establishing causality between STAT3 activation and transformation.\",\n      \"evidence\": \"SH2-domain cysteine substitution (Stat3-C), dimerization/DNA-binding/reporter assays, soft agar and nude mouse xenograft\",\n      \"pmids\": [\"10458605\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not enumerate the transformation-driving target genes\", \"Engineered mutant rather than naturally occurring tumor lesion\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined a physiological in vivo requirement for STAT3 in tissue remodeling, showing it initiates epithelial apoptosis during mammary involution.\",\n      \"evidence\": \"Mammary-epithelium-specific lox/Cre conditional knockout, involution and apoptosis assays\",\n      \"pmids\": [\"10959419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pro-apoptotic effector genes downstream of STAT3 in involution not fully resolved\", \"Tissue-specific finding may not generalize\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed STAT3 in developmental morphogenesis, showing maternal Wnt/beta-catenin activates Stat3 to drive gastrulation cell movements without altering fate.\",\n      \"evidence\": \"Dominant-negative Stat3, cell tracing, transplantation for cell-autonomy in zebrafish\",\n      \"pmids\": [\"11879641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link from Wnt/beta-catenin to Stat3 activation undefined\", \"Effector genes mediating migration versus convergence not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved STAT3 nucleocytoplasmic shuttling, identifying a post-stimulation NES and basal NES elements supporting phosphorylation-independent CRM1-dependent export.\",\n      \"evidence\": \"Leptomycin B treatment, NES mutagenesis, subcellular localization\",\n      \"pmids\": [\"12588893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import machinery and karyopherins not mapped\", \"Functional role of basal unphosphorylated nuclear STAT3 unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified transcriptional repression of STAT3 via a corepressor, showing Tip60 binds STAT3 and recruits HDAC7 to silence STAT3 target genes.\",\n      \"evidence\": \"Endogenous Co-IP, reporter assays, siRNA/overexpression, c-myc readout\",\n      \"pmids\": [\"12551922\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide scope of Tip60/HDAC7 repression unknown\", \"Single-lab; reciprocal validation limited\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Expanded the STAT3 interactome to modulators of its activity through STRA13 binding to phosphorylated STAT3 and PIAS3 redistribution from MITF to STAT3.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown/Co-IP with phospho-STAT3, reporter and apoptosis assays; Co-IP and gene expression in MITF-mutant cells\",\n      \"pmids\": [\"15223310\", \"15572665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contexts where these interactions dominate unclear\", \"Direct versus indirect effects on STAT3 targets not fully separated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established STAT3 as a transcriptional repressor of p53, linking oncogenic STAT3 to apoptosis evasion.\",\n      \"evidence\": \"ChIP of in vivo binding, p53 promoter mutagenesis, STAT3 knockdown with p53/apoptosis readout\",\n      \"pmids\": [\"16107692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors mediating repression at the p53 promoter not identified\", \"Partial abrogation by single-site mutation implies additional elements\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed a transcription-independent cytoplasmic function, showing unphosphorylated STAT3 binds stathmin to promote microtubule polymerization and migration.\",\n      \"evidence\": \"Co-IP/pulldown with stathmin, microtubule polymerization and migration assays\",\n      \"pmids\": [\"16835434\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of STAT3-stathmin binding undefined\", \"In vivo relevance to metastasis not established\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed that productive IL-6/STAT3 signaling requires endocytic trafficking, with phosphorylated STAT3 associating with early endosomes.\",\n      \"evidence\": \"Fractionation, EM, immunofluorescence, dominant-negative/active endocytic regulators with STAT3 reporter\",\n      \"pmids\": [\"16407171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endosomal scaffold tethering STAT3 not identified\", \"Whether endosomal compartment is the site of phosphorylation unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a nuclear serine kinase input, showing ZIP kinase specifically phosphorylates STAT3 Ser727 to enhance transcription.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay with phospho-Ser727 detection, siRNA, reporter assay\",\n      \"pmids\": [\"16219639\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide Ser727-dependent target set not defined\", \"Single-lab specificity claim among STATs\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified a second negative regulator, KAP1/TIF1beta, that binds STAT3 and limits IL-6-driven transcription and nuclear pSer727-STAT3 accumulation.\",\n      \"evidence\": \"Yeast two-hybrid, endogenous Co-IP, siRNA, reporter and nuclear pSer727 immunostaining\",\n      \"pmids\": [\"18037959\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which KAP1 controls pSer727 levels unresolved\", \"Direct versus indirect repression not separated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Distinguished pathway-specific STAT3 functions, defining a JAK2/STAT2/STAT3 axis required for myogenic differentiation separate from a proliferative JAK1/STAT1/STAT3 pathway.\",\n      \"evidence\": \"siRNA and JAK2 small-molecule inhibition, differentiation assays, qPCR of MyoD/MEF2/IGF2/HGF\",\n      \"pmids\": [\"18835816\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT3 occupancy at the differentiation target genes not shown\", \"Mechanism partitioning STAT3 between the two axes unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Uncovered a self-amplifying circuit, with STAT3 transactivating S1PR1 which in turn upregulates JAK2/IL-6 to sustain persistent STAT3 activation in cancer.\",\n      \"evidence\": \"ChIP, S1PR1 silencing in tumor and immune cells, xenograft growth/metastasis, JAK2 activity assay\",\n      \"pmids\": [\"21102457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative thresholds sustaining the loop not defined\", \"Tissue contexts where the loop is dispensable unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Characterized a direct chaperone interaction, showing Hsp90beta binds STAT3 in a manner requiring an intact DNA-binding domain.\",\n      \"evidence\": \"Surface plasmon resonance of recombinant proteins, RR414/417A mutagenesis, oligonucleotide pulldown, confocal colocalization\",\n      \"pmids\": [\"22271514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Hsp90beta binding for STAT3 stability/activity not established\", \"Single-lab; in vivo relevance untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovered a noncanonical activation mode, with GSK-3alpha/beta dually phosphorylating Thr714/Ser727 to drive gene induction independently of Tyr705 upon EGFR/PAR-1 co-activation.\",\n      \"evidence\": \"Quantitative LC-MS/MS, Thr714/Ser727 mutagenesis, GSK-3alpha/beta depletion, reporter assay, clinical tissue comparison\",\n      \"pmids\": [\"24615012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes specifically driven by the dual phosphoform not enumerated\", \"Structural effect of dual phosphorylation on STAT3 not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined STAT3 antagonism of TGF-beta, showing activated STAT3 binds Smad3 and blocks Smad3-Smad4 complex formation and DNA binding.\",\n      \"evidence\": \"In vivo/in vitro Co-IP, domain mapping, Smad3-Smad4 disruption assay, STAT3 knockdown with TGF-beta phenotype readouts\",\n      \"pmids\": [\"26616859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural interface of the STAT3-Smad3 complex undefined\", \"Crosstalk balance in normal tissue not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established transcriptional control of STAT3 levels, identifying ZNF341 as a direct activator of the STAT3 promoter whose loss causes an AD-HIES-like immunodeficiency.\",\n      \"evidence\": \"Promoter binding/luciferase assays, ZNF341 mutant translocation, patient cells, STAT3 mRNA/protein quantification in consanguineous families\",\n      \"pmids\": [\"29907690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other transcriptional regulators of STAT3 not mapped\", \"Mechanism connecting reduced STAT3 to Th17 loss only partially defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked STAT3 to epigenetic remodeling, showing a vitamin D-induced VDR-pSTAT3-TET2 complex drives DNA demethylation establishing tolerogenic dendritic cells.\",\n      \"evidence\": \"Co-IP of trimeric complex, JAK2 inhibition, DNA methylation analysis, DC tolerogenesis assay\",\n      \"pmids\": [\"35045292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide demethylation sites dependent on the complex not mapped\", \"Single-lab; direct ternary complex stoichiometry unconfirmed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined an antiviral restraint function, showing RIG-I/MAVS/Syk-driven STAT3 Y705 phosphorylation limits excessive type I/III interferon during influenza A infection.\",\n      \"evidence\": \"STAT3-Y705F knockin mice, IAV infection, IFN measurement, IFNAR1/IFNLR1 epistatic rescue, viral load\",\n      \"pmids\": [\"37440406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT3 target genes repressing IFN not enumerated\", \"Mechanism of IL-6-independent Y705 phosphorylation not fully resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse STAT3 inputs (tyrosine versus multi-serine/threonine phosphoforms, cofactor occupancy, endosomal localization) are integrated into context-specific transcriptional and non-transcriptional outputs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking distinct phosphoforms to specific gene programs\", \"Determinants selecting transcriptional versus cytoskeletal/mitochondrial functions undefined\", \"Structural basis of corepressor versus coactivator switching unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 9, 15, 19]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 9, 16]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 10]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 9, 12, 13]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 9, 15, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 20, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 9, 15, 17]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 14, 22]}\n    ],\n    \"complexes\": [\n      \"gp130/JAK1-STAT3 receptor complex\",\n      \"VDR-pSTAT3-TET2 complex\"\n    ],\n    \"partners\": [\n      \"IL6ST\",\n      \"JAK1\",\n      \"Smad3\",\n      \"STMN1\",\n      \"HSP90AB1\",\n      \"KAP1\",\n      \"PIAS3\",\n      \"DAPK3\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":10,"faith_pct":90.0}}